AIM: To retrospectively analyze the pathological outcomes of patients meeting the Prostate Cancer Research International Active Surveillance (PRIAS) criteria who had undergone radical prostatectomy (RP).
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
PATIENTS AND METHODS: Out of 2014 patients recruited for minimally invasive RP between 2008 and 2014 in 7 centers, 226 (11.2%) met the modified PRIAS criteria (clinical stage T1c/T2, PSA < 10 ng/ml, 1--2 positive biopsy cores and Gleason score < 6).
RESULTS: At pathological evaluation, Gleason score upgrade was reported in 47.3% of patients; 74 (32.7%), 10 (4.4%), 9 (3.9%) patients showed RP Gleason sum 7, 8 and 9, respectively. Upstaging was reported in 135 patients (59.7%). 12 (5.3%) and 4 (1.7 %) patients had T3a and T3b pathological stage respectively.
CONCLUSIONS: Notwithstanding the PRIAS criteria can identify some PCa patients as low--risk, at pathological evaluation some of them harbored intermediate-- or high--risk disease. According to our data, patients eligible for AS should be carefully counseled about possible disease understaging.
Grasso AA, Cozzi G, De Lorenzis E, Ceruti C, Crivellaro S, Falsaperla M, Minervini A, Masieri L, Serni S, Porreca A, Zaramella S, Rocco B. Are you the author?
Clinica Urologica I, Universita`degli Studi di Milano, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy.
Reference: Minerva Urol Nefrol. 2015 Mar 3. Epub ahead of print.